We are live on
!
Find out more
NAM
Needelman Asset Management Portfolio holdings
AUM
$46M
1-Year Est. Return
8.27%
This Fund
S&P 500
This Quarter
Est. Return
+3.71%
1 Year Est. Return
+8.27%
3 Year Est. Return
+30.52%
5 Year Est. Return
+74.86%
10 Year Est. Return
–
AUM
$40.7M
AUM Growth
+$1.87M
(+4.8%)
Cap. Flow
+$771K
Cap. Flow
% of AUM
1.89%
Top 10 Holdings %
Top 10 Hldgs %
36.13%
Holding
38
New
1
Increased
11
Reduced
16
Closed
–
Avg Time Held
14.6
quarters
Top 10 Avg Time Held
8.5
quarters
Top 20 Avg Time Held
10.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$1.18M |
| 2 |
Fluor
FLR
|
+$99.3K |
| 3 |
Mondelez International
MDLZ
|
+$55.2K |
| 4 |
GE Aerospace
GE
|
+$49.2K |
| 5 |
Emerson Electric
EMR
|
+$23.8K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$189K |
| 2 |
Bank of America
BAC
|
+$177K |
| 3 |
Elevance Health
ELV
|
+$139K |
| 4 |
Microsoft
MSFT
|
+$71.2K |
| 5 |
Bristol-Myers Squibb
BMY
|
+$29.2K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 26.59% |
| 2 | Financials | 22.27% |
| 3 | Technology | 15.05% |
| 4 | Consumer Staples | 11.59% |
| 5 | Industrials | 10.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Bank of America
BAC
$375B
| $1.62M | 3.97% |
63,836
-7,300
| -10% | -$177K |
2013 Q2
17 quarters
|
|
|
2
UnitedHealth
UNH
$333B
| $1.58M | 3.89% |
8,077
-980
| -11% | -$189K |
2013 Q2
17 quarters
|
|
|
3
Elevance Health
ELV
$87B
| $1.55M | 3.8% |
8,140
-730
| -8% | -$139K |
2013 Q2
17 quarters
|
|
|
4
Microsoft
MSFT
$3.88T
| $1.54M | 3.78% |
20,690
-975
| -5% | -$71.2K |
2015 Q3
8 quarters
|
|
5
JPMorgan Chase
JPM
$881B
| $1.5M | 3.69% |
15,743
-115
| -0.7% | -$10.6K |
2013 Q2
17 quarters
|
|
6
Abbott
ABT
$170B
| $1.43M | 3.51% |
26,782
| – | – |
2013 Q2
17 quarters
|
|
7
Markel Group
MKL
$21.9B
| $1.43M | 3.5% |
1,335
-5
| -0.4% | -$5.17K |
2013 Q4
15 quarters
|
|
8
Berkshire Hathaway Class B
BRK.B
$1.09T
| $1.4M | 3.44% |
7,645
-50
| -0.6% | -$8.84K |
2013 Q2
17 quarters
|
|
9
Honeywell
HON
$65.5B
| $1.39M | 3.42% |
10,883
-149
| -1% | -$18.5K |
2013 Q2
17 quarters
|
|
10
Johnson & Johnson
JNJ
$618B
| $1.27M | 3.13% |
9,795
-40
| -0.4% | -$5.3K |
2013 Q2
17 quarters
|
|
11
NCR Voyix
VYX
$953M
| $1.27M | 3.12% |
55,216
| – | – |
2017 Q2
1 quarter
|
|
|
12
Gilead Sciences
GILD
$182B
| $1.25M | 3.08% |
+15,490
| New | +$1.18M |
2017 Q3
0 quarters
|
|
13
Intel
INTC
$566B
| $1.25M | 3.07% |
32,845
+100
| +0.3% | +$3.55K |
2013 Q2
17 quarters
|
|
14
Diageo
DEO
$48.4B
| $1.22M | 2.99% |
9,202
-40
| -0.4% | -$5.17K |
2013 Q2
17 quarters
|
|
15
Aon
AON
$58.8B
| $1.2M | 2.94% |
8,200
-100
| -1% | -$14K |
2013 Q2
17 quarters
|
|
16
Chubb
CB
$133B
| $1.16M | 2.84% |
8,111
| – | – |
2016 Q1
6 quarters
|
|
17
Chevron
CVX
$415B
| $1.14M | 2.81% |
9,735
+35
| +0.4% | +$3.82K |
2013 Q2
17 quarters
|
|
|
18
Emerson Electric
EMR
$88.7B
| $1.12M | 2.75% |
17,790
+395
| +2% | +$23.8K |
2013 Q2
17 quarters
|
|
19
Pfizer
PFE
$159B
| $1.08M | 2.66% |
31,963
-105
| -0.3% | -$3.38K |
2013 Q2
17 quarters
|
|
20
Procter & Gamble
PG
$350B
| $1.03M | 2.53% |
11,325
| – | – |
2013 Q2
17 quarters
|
|
21
Apple
AAPL
$4.97T
| $933K | 2.29% |
24,224
-100
| -0.4% | -$3.88K |
2013 Q2
17 quarters
|
|
|
22
GE Aerospace
GE
$317B
| $933K | 2.29% |
8,052
+407
| +5% | +$49.2K |
2013 Q2
17 quarters
|
|
|
23
Fluor
FLR
$6.82B
| $922K | 2.26% |
21,905
+2,395
| +12% | +$99.3K |
2013 Q2
17 quarters
|
|
|
24
Bristol-Myers Squibb
BMY
$122B
| $905K | 2.22% |
14,200
-500
| -3% | -$29.2K |
2013 Q2
17 quarters
|
|
25
AbbVie
ABBV
$481B
| $894K | 2.2% |
10,057
| – | – |
2013 Q2
17 quarters
|
|
Similar funds
PRHC
BC
SCPM
SAM
BCP
AVA
GG
SM
Needelman Asset Management's Q3 2017 Portfolio in Review
As of Q3 2017, Needelman Asset Management held 38 positions worth $40.7M, up 4.8% from $38.8M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Trading was light in Q3 2017: portfolio turnover was 2.6%. Needelman Asset Management opened 1 new position and made no exits, leaving the 38-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 24% a quarter earlier, followed by Financials and Technology.
- Needelman Asset Management's largest Q3 2017 buy was Gilead Sciences: 15,490 shares worth $1.25M.
- Needelman Asset Management added most to Fluor in Q3 2017, an estimated $99.3K increase.
- Needelman Asset Management's biggest Q3 2017 reduction was UnitedHealth, cutting an estimated $189K.
- Needelman Asset Management's ten largest holdings make up 36% of its $40.7M portfolio in Q3 2017.
- Needelman Asset Management opened 1 new position and closed 0 in Q3 2017.
- Needelman Asset Management's portfolio value rose 4.8% quarter-over-quarter to $40.7M.
Based on Needelman Asset Management's 13F filing for Q3 2017, filed 5 Oct 2017.